This is a Phase 1, open-label, drug-drug interaction (DDI) study of ALT-801 under steady
state conditions on concomitantly administered medications in healthy subjects. The study
will evaluate the effect of ALT-801 on the pharmacokinetics (PK) of metformin, warfarin,
atorvastatin, digoxin, and the combined oral contraceptive (OC)
ethinylestradiol/levonorgestrel. The study will be conducted in 3 parts, as described below.
Each part will have 2 periods in a fixed sequence, where the first period is without ALT-801
administration and the second is with ALT-801 at steady state.